

# The Role of Mesenchymal Stem Cells Secretome in Regeneration of Thyroid Tissue Damage after Thyroid Lobectomy: A Literature Review

## Abstract

Mesenchymal Stem Cells (MSC) are a type of multipotent stem cell that originates from the mesoderm and ectoderm in early development and can differentiate into differentiate into: 1. Ectodermal derivatives such as: neurons, keratocytes and keratinocytes; 2. Endodermal derivatives such as: hepatocytes and pancreatic  $\beta$  cells. MSCs were first discovered in the bone marrow, but in recent research they have been found in many other body tissues, such as the lungs, pancreas, liver, adipose tissue, synovial tissue, muscles, bones, amniotic fluid and umbilical cord blood. MSCs vary in content, accessibility, proliferation ability, immunomodulatory capacity, and the cytokines they secrete, and have different therapeutic potential based on different sources. Recent evidences showed that even the secreted factor including secretome, microvesicles, or exosomes alone without the cell may repair damaged tissue in various conditions. In this review, we summarize the latest research which aims to provide an overview of the influence of the mesenchymal stem cells secretome in regenerating damaged follicular thyroid tissue after thyroid lobectomy, so that in the future research can be carried out on this matter to minimize complications after thyroid lobectomy, can even regenerate follicular thyroid tissue, and can be an option treatment to help overcome the current challenges of hormone replacement therapy.

**Keywords:** Mesenchymal Stem Cells, Mesenchymal Stem Cells Secretome, Follicular Thyroid Nodule, Thyroid Lobectomy

## Introduction


Mesenchymal Stem Cells (MSC) are a type of multipotent stem cell that originates from the mesoderm and ectoderm in early development and can differentiate into differentiate into: 1. Ectodermal derivatives such as: neurons, keratocytes and

keratinocytes; 2. Endodermal derivatives such as: hepatocytes and pancreatic  $\beta$  cells [1, 2]. MSCs were first discovered in the bone marrow, but in recent research they have been found in many other body tissues, such as the lungs, pancreas, liver, adipose tissue, synovial tissue, muscles, bones, amniotic fluid and umbilical cord blood [3, 4]. MSCs vary in content, accessibility, proliferation ability, immunomodulatory capacity, and the cytokines they secrete, and have different therapeutic potential based on different sources. Recent evidences showed that even the secreted factor including microvesicles, or exosomes alone without the cell may repair damaged tissue in various conditions [5]. Previously, there had been no research discussing the secretome regeneration potential of mesenchymal stem cells in thyroid tissue damage after thyroid lobectomy. In this review, we summarize the latest research which aims to provide an overview of the influence of the mesenchymal stem cells secretome in regenerating damaged follicular thyroid tissue after thyroid lobectomy, so that in the future research can be carried out on this matter to minimize complications after thyroid lobectomy, can even regenerate follicular thyroid tissue, and can be an option treatment to help overcome the current challenges of hormone replacement therapy.

#### Mesenchymal Stem Cells Secretome Characteristics

MSCs produce and secrete a wide variety of bioactive molecules in response to different microenvironment conditions and are even referred to as “trophic factories”. The combination of all the trophic factors or molecules secreted by these cells to the extracellular space is known as secretome [13]. Mesenchymal Stem Cells secretome have the ability to produce a variety of autocrine and paracrine factors including cytokines, extracellular matrix (ECM) proteases, chemokines and growth factors, thus allowing the possibility of being used as a potential source of cell-free based therapy [6]. In addition, MSC secretome also contain exosomes and extracellular vesicles [93]. Exosomes can contain lipids, miRNAs, long noncoding RNAs that regulate various related signaling inflammation pathways [7]. Identification and characterization of all forming biomolecules secretome is difficult to achieve, but can improve understanding of the profile of secreted factors and provides information about its regulation, function, and clinical applications [8]. The MSCs can influence surrounding cells and regulate various biological processes [9]. Overall, these characteristics indicate that MSCs have potential

cell therapy for regeneration of damaged tissue with different tissue systems, such as heart, bones, kidneys, lungs, including thyroid tissue [7]. Summary information on the secretome potential of mesenchymal stem cells can be seen in **Figure 1**.



**Figure 1.** Summary of various soluble factors secreted by mesenchymal stem cells and their potency [6].

### Thyroid Lobectomy Indications for which Mesenchymal Stem Cells Secretome can be Administered

The indication for choosing thyroid lobectomy or lobectomy plus isthmusectomy (hemithyroidectomy) for thyroid nodule is to optimize oncological outcomes, such as disease-free and disease-specific survival, maintaining surgical morbidity and long-term treatment effects. The complication rate of thyroid lobectomy is lower than total thyroidectomy. In a large meta-analysis study of 50,445 patients, found the pooled relative risk for postoperative complications was 10.67 for total thyroidectomy versus thyroid lobectomy. Among the relative risks found were temporary recurrent nerve palsy of 1.69, permanent recurrent nerve palsy of 1.85, and hematoma of 2.58, while the relative risk for temporary hypocalcemia was 3.1 and permanent hypocalcemia was 1.69

[10].

The advantages of thyroid lobectomy, combined with a large body of data confirm the excellent survival of patients with low-risk cancers treated with lobectomy. This has led to a shift towards lobectomy [11]. In a review outlined the therapeutic potential of mesenchymal stem cells in regenerating thyroid cells and modulating thyroid function. Mesenchymal stem cells represent a promising form of treatment for thyroid disorders [12].


#### Potential Regeneration of Mesenchymal Stem Cells Secretome in Thyroid Tissue Damage

Although research on the secretome regenerative potential of MSCs is still scarce compared to research on the regenerative potential of MSCs, preclinical trials conducted to date have shown significant positive results and few side effects associated with the use of this product. In a recent review the MSC secretome has a role as the main trigger of regenerative activity which describes the main components of the soluble and vesicular parts as well as the main biological processes in tissue regeneration that are positively influenced by these bioactive components [13].

In recent research, MSCs were shown to secrete IL-1Ra (interleukin 1 receptor antagonist) which is a competitive inhibitor of IL-1 (Interleukin-1). Production of IL-1Ra induces M2-like macrophage polarization and inhibits B cell differentiation [14] and in vitro stops the production of TNF- $\alpha$  by macrophages [15]. Growth factors including VEGF (vascular endothelial growth factor), LIF (leukemia inhibitory factor), and HGF-1 (hepatocyte growth factor-1) are also contained in the secretome which have potential as regenerative agents [15].

Many studies have proven that there is a synergistic action of small molecules secreted by MSCs that can reduce cell injury and increase tissue repair capacity [25, 26]. The proximity of the host cell is not necessary because the soluble molecules are carried to the target cells. Therefore, the secretome of MSCs, including extracellular vesicles (EVs) derived from MSCs (MSC-EVs), is of more interest than MSC transplantation itself. EVs represent an intercellular communication system, which is used by many types of cells capable of carrying many molecules in one package to specific target cells, so they can be useful in therapy (**Figure 2**) [27, 29]. The medical applications of vesicles change along

with the composition and structure of the stem cells [20]. In this regard, MSC-EVs represent a powerful regenerative agent capable of maintaining or restoring tissue homeostasis [28]. Several studies suggest that the secretome of mesenchymal stem cells has regenerative potential against tissue damage. The regenerative potential of the secretome of mesenchymal stem cells against more specific thyroid tissue damage still requires further review and experimental research for use in clinical therapy.



**Figure 2.** Overview of the MSC secretome.

The secretome comprises of soluble proteins and secreted extracellular vesicles. The proteins include biologically active factors such as cytokines (e.g., interleukin 10, and tumor necrosis factor- $\alpha$ ), chemokines (e.g., eotaxin-3), and growth factors (e.g., hepatocyte growth factor and transforming growth factor- $\beta$  isoform 3). The vesicular factors include exosomes and microvesicles [29].

### Clinical and Experimental Trials

Based on recent findings, researchers and physicians have shifted their therapeutic paradigm from passive reduction of tissue damage to active improvement in tissue regeneration and function. Although for almost two decades cell-based therapy was considered a philosopher's stone for enhancing tissue regeneration, this concept began to falter after the research of Gnechchi et al. in 2005 [16] that one of the first groups to

show that paracrine factors present in the secretome released from mesenchymal stem cells are capable of promoting tissue regeneration. In subsequent years, subsequent studies from around the world supported the hypothesis that paracrine factors, rather than cellular factors, were indeed responsible for the beneficial effects [17-21].

The secretome of mesenchymal stem cells consists of all factors released either actively or passively from the cell and contains, among others, soluble proteins such as cytokines, chemokines, and growth factors, lipids, free nucleic acids, and extracellular vesicles (EVs).

The latter can be subdivided based on size, density, surface markers and origin into apoptotic bodies, microparticles and exosomes. In particular, exosomes have recently become the focus of research based on their high capacity to interact with target cells and their ability to selectively modify cell signals [22]. One of the most comprehensive articles summarizing the role of EVs in the field of tissue regeneration and regenerative medicine was recently published by Silva and co-workers [23]. Recently there has been no review or clinical research regarding the role of mesenchymal stem cells Secretome in regeneration of thyroid tissue damage after thyroid lobectomy.

In recent decades, thyroid lobectomy has been primarily used to study the effect of reduced levels of endogenous thyroid hormone or exogenously administered thyroid hormone on liver regeneration, enzymatic activity/function, or levels of thyroid hormone-regulated molecules in the brain, hypothalamus, pituitary, and liver. Other studies used thyroid lobectomy to perform quantitative analysis of thyroid function after inoculating thyroid cells into rodents undergoing thyroid lobectomy/total thyroidectomy and its association with neoplasms [24].

In a study using a rat model for thyroid regeneration, thyroid lobectomy was performed to study the effect of thyroid lobectomy on the morphology and gene expression of the remaining tissue/cells. In this study, thyroid lobectomy was performed to remove the entire thyroid lobe and ~2/5 of the tail segments of the other lobe. During this study, it was noted that the central area of both thyroid lobes (without thyroid lobectomy) served as a center of proliferation where many immature microfollicles, and bromodeoxyuridine (BrdU)-positive and/or C cells were located. One week after thyroid lobectomy, serum

TSH levels increased drastically, resulting in goitrogenesis, which almost completely resolved within 2 weeks after thyroid lobectomy. At that time, a marked increase in the number of BrdU-positive cells and cells with clear or faint eosinophilic cytoplasm was seen in the central area and areas continuing to the edge of the cut. Some clear cells were positive for BrdU, showed active proliferation, and expressed Foxa2, a definitive endoderm lineage marker. Microarray followed by pathway analysis revealed that the expression of genes involved in embryonic development and cancer was affected by thyroid lobectomy. Electron microscopy shows that clear cells are scattered in the cytoplasm, and retain features reminiscent of C cells that have dense neuroendocrine granules or follicular cells juxtaposed to the lumen with microvilli. Overall, clear cells may be immature cells that were previously C cells or follicular cells that play a role in repair, regeneration of the thyroid gland, and/or goitrogenesis after thyroid lobectomy [24].

#### Future Direction

The limited experimental research and even the absence of clinical research on the potential for regenerating the secretome of mesenchymal stem cells against damage to thyroid follicular tissue after thyroid lobectomy, is a challenge for researchers in the future. The author hopes that this review can be used as a basic for future experimental research and can be developed into clinical research.

#### Conclusion

In conclusion, MSCs produce a large number of bioactive molecules and extracellular vesicles, known as the secretome having important paracrine effects on surrounding cells and tissues. The use of MSC secretomes in tissue regeneration therapy would avoid the problems associated with MSC-based therapies, such as low cell viability and engraftment, which importantly limit their therapeutic efficacy, or the downsides and effects associated with administration of these cells. In the case of administering MSC secretome to damaged thyroid tissue after thyroid lobectomy, it is possible to become a regenerative agent in this condition. Many studies state that the MSC secretome has regenerative potential in tissue damage. The author hopes that there will be research regarding the administration of MSC secretome to post-operative tissue damage,

especially to thyroid tissue damage after thyroid lobectomy, to develop insight into MSC-based regenerative therapy.

#### References

1. Sheng, G. The developmental basis of mesenchymal stem/stromal cells (MSCs). *BMC Dev. Biol.* 2015, *15*, 44. DOI: 10.1186/s12861-015-0094-5
2. Putra, A. Basic Molecular Stem Cell. Unissula Press. 2019, *1*, 214.
3. Costela-Ruiz, V.J.; Melguizo-Rodriguez, L.; Bellotti, C.; Illescas-Montes, R.; Stanco, D.; Arciola, C.R.; Lucarelli, E. Different Sources of Mesenchymal Stem Cells for Tissue Regeneration: A Guide to Identifying the Most Favorable One in Orthopedics and Dentistry Applications. *Int. J. Mol. Sci.* 2022, *23*, 6356. DOI: 10.3390/ijms23116356
4. Zhou, J.; Shi, Y. Mesenchymal stem/stromal cells (MSCs): Origin, immune regulation, and clinical applications. *Cell. Mol. Immunol.* 2023, *20*, 555–557. DOI: 10.1038/s41423-023-01034-9
5. Kim HO, Choi S. Mesenchymal stem cell-derived secretome and microvesicles as a cell-free therapeutics for neurodegenerative disorders. *Tissue Eng Regen Med.* 2013; *10*: 93-101. DOI: 10.1007/s13770-013-0010-7
6. González-González A, García-Sánchez D, Dotta M, Rodríguez-Rey JC, Pérez-Campo FM. Mesenchymal stem cells secretome: The cornerstone of cell-free regenerative medicine. *World J Stem Cells* 2020; *12*(12): 1529-1552. PMID: 33505599. DOI: 10.4252/wjsc.v12.i12.1529
7. Gao, F.; Yu, L.; Zhang, N.; Zhang, Y.; Wang, R.; Zhao, J. Long noncoding RNAs and their regulatory network: Potential therapeutic targets for adult moyamoya disease. *World Neurosurg.* 2016, *93*, 111–119. DOI: 10.1016/j.wneu.2016.05.081
8. Ranganath, S.H.; Levy, O.; Inamdar, M.S.; Karp, J.M. Harnessing the mesenchymal stem cell secretome for the treatment of cardiovascular disease. *Cell Stem Cell* 2012, *10*, 244–258. DOI: 10.1016/j.stem.2012.02.005
9. Ahangar, P.; Mills, S.J.; Cowin, A.J. Mesenchymal Stem Cell Secretome as an Emerging Cell-Free Alternative for Improving Wound Repair. *Int. J. Mol. Sci.* 2020, *21*, 7038. DOI: 10.3390/ijms21197038

10. Kandil, E.; Krishnan, B.; Noureldine, S.I.; Yao, L.; Tufano, R.P. Hemithyroidectomy: A Meta-Analysis of Postoperative Need for Hormone Replacement and Complications. *ORL* 2013, *75*, 6–17. DOI: 10.1159/000345498
11. Lang, B.H.-H.; Wong, C.K.H. Lobectomy is a more Cost-Effective Option than Total Thyroidectomy for 1 to 4 cm Papillary Thyroid Carcinoma that do not Possess Clinically Recognizable High-Risk Features. *Ann. Surg. Oncol.* 2016, *23*, 3641–3652. DOI: 10.1245/s10434-016-5280-6
12. Sunyi Ye, Zhu Lixian Zhu. Stem Cell Therapy for Thyroid Diseases: Progress and Challenges. *Curr Ther Res Clin Exp.* 2022; 96: 100665. Published online 2022 Mar 5. DOI: 10.1016/j.curtheres.2022.100665
13. Alberto González-González, Daniel García-Sánchez, Monica Dotta, José C Rodríguez-Rey, Flor M Pérez-Campo. Mesenchymal stem cells secretome: The cornerstone of cell-free regenerative medicine. *World J Stem Cells.* 2020 Dec 26; 12(12): 1529–1552. Published online 2020 Dec 26. DOI: 10.4252/wjsc.v12.i12.1529
14. Luz-Crawford P., Djouad F., Toupet K., Bony C., Franquesa M., Hoogduijn M.J., Jorgensen C., Noël D. Mesenchymal Stem Cell-Derived Interleukin 1 Receptor Antagonist Promotes Macrophage Polarization and Inhibits B Cell Differentiation: MSC-IL1RA Inhibits B Cell Differentiation. *Stem Cells.* 2016;34:483–492. DOI: 10.1002/stem.2254
15. Sharon Eleuteri and Alessandra Fierabracci. Insights into the Secretome of Mesenchymal Stem Cells and Its Potential Applications. *Int J Mol Sci.* 2019 Sep; 20(18): 4597. Published online 2019 Sep 17. DOI: 10.3390/ijms20184597
16. Gnechi M, He H, Liang OD, et al. Paracrine action accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cells. *Nat Med* 2005;11:367-8. DOI: 10.1038/nm0405-367
17. Ankersmit HJ, Hoetzenecker K, Dietl W, et al. Irradiated cultured apoptotic peripheral blood mononuclear cells regenerate infarcted myocardium. *Eur J Clin Invest* 2009;39:445-56. DOI: 10.1111/j.1365-2362.2009.02111.x
18. Lichtenauer M, Mildner M, Baumgartner A, et al. Intravenous and intramyocardial injection of apoptotic white blood cell suspensions prevents ventricular remodelling by increasing elastin expression in cardiac scar tissue after myocardial infarction. *Basic Res Cardiol* 2011;106:645-55. DOI: 10.1007/s00395-011-0173-0

19. Lichtenauer M, Mildner M, Hoetzenecker K, et al. Secretome of apoptotic peripheral blood cells (APOSEC) confers cytoprotection to cardiomyocytes and inhibits tissue remodelling after acute myocardial infarction: a preclinical study. *Basic Res Cardiol* 2011;106:1283-97. DOI: 10.1007/s00395-011-0224-6
20. Beer L, Mildner M, Gyöngyösi M, et al. Peripheral blood mononuclear cell secretome for tissue repair. *Apoptosis* 2016;21:1336-53. DOI: 10.1007/s10495-016-1292-8
21. Korf-Klingebiel M, Rebold MR, Klede S, et al. Myeloid-derived growth factor (C19orf10) mediates cardiac repair following myocardial infarction. *Nat Med* 2015;21:140-9. DOI: 10.1038/nm.3778
22. Kourembanas S. Exosomes: vehicles of intercellular signaling, biomarkers, and vectors of cell therapy. *Annu Rev Physiol* 2015;77:13-27. DOI: 10.1146/annurev-physiol-021014-071641
23. Silva AM, Teixeira JH, Almeida MI, et al. Extracellular Vesicles: Immunomodulatory messengers in the context of tissue repair/regeneration. *Eur J Pharm Sci* 2017;98:86-95. DOI: 10.1016/j.ejps.2016.09.017
24. Hioko Kimura. Thyroid Regeneration: How Stem Cells Play a Role? *Front. Endocrinol.*, 14 April 2014 Sec. Thyroid Endocrinology. Volume 5 - 2014. DOI: 10.3389/fendo.2014.00055
25. Caplan A.I., Dennis J.E. Mesenchymal Stem Cells as Trophic Mediators. *J. Cell. Biochem.* 2006;98:1076–1084. DOI: 10.1002/jcb.20886.
26. Yeh Yeo R.W., Chai R., Hian K., Kiang S. Exosome: A Novel and Safer Therapeutic Refinement of Mesenchymal Stem Cell. *J. Circ. Biomark.* 2013; 1 DOI: 10.5772/57460
27. Fierabracci A., Del Fattore A., Luciano R., Muraca M., Teti A., Muraca M. Recent Advances in Mesenchymal Stem Cell Immunomodulation: The Role of Microvesicles. *Cell Transplant.* 2015;24:133–149. DOI: 10.3727/096368913X675728
28. Lai R.C., Yeo R.W.Y., Lim S.K. Mesenchymal Stem Cell Exosomes. *Semin. Cell Dev. Biol.* 2015;40:82–88. DOI: 10.1016/j.semcdb.2015.03.001
29. Julia Driscoll, Tushar Patel. The mesenchymal stem cell secretome as an acellular regenerative therapy for liver disease. *J Gastroenterol* (2019) 54:763–773. DOI: 10.1007/s00535-019-01599-1

UNDER PEER REVIEW